Synthesis of Ranolazine Metabolites and Their Anti-myocardial Ischemia Activities
作者:Zhangyu Yao、Shubo Gong、Teng Guan、Yunman Li、Xiaoming Wu、Hongbin Sun
DOI:10.1248/cpb.57.1218
日期:——
The anti-anginal drug Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, is thought to modulate the metabolism during myocardial ischemia by activating pyruvate dehydrogenase activity to promote glucose oxidation. Ranolazine and its five principal metabolites: CVT-2512, CVT-2513, CVT-2514, CVT-2738 and CVT-4786, were synthesized. The effect of Ranolazine and its metabolites on the ECG (electrocardiogram) of mice with myocardial ischemia induced by isoprenaline and their effect on alleviating the symptom of myocardial ischemia were tested and compared. The results showed that CVT-2738 and CVT-2513 could be protective against mice myocardial ischemia induced by isoprenaline. Within all the metabolites tested in this study, CVT-2738 exhibited the best potency, however, it was still less potent than Ranolazine.
抗心绞痛药物雷诺嗪是一种部分脂肪酸氧化(pFOX)抑制剂,它通过激活丙酮酸脱氢酶活性来促进葡萄糖氧化,从而在心肌缺血期间调节代谢。雷诺嗪及其五种主要代谢物:CVT-2512、CVT-2513、CVT-2514、CVT-2738和CVT-4786,已被合成。测试并比较了雷诺嗪及其代谢物对异丙肾上腺素诱导的小鼠心肌缺血的心电图(ECG)的影响,以及它们缓解心肌缺血症状的效果。结果显示,CVT-2738和CVT-2513对异丙肾上腺素诱导的小鼠心肌缺血具有保护作用。在所有本研究测试的代谢物中,CVT-2738显示出最佳的效能,尽管其效能仍低于雷诺嗪。